Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tisagenlecleucel Re-infusion in Pediatric/AYA ALL
NCT04225676Phase 2Terminated
- Sponsor
- Novartis
- Start
- Oct 2020
- Primary completion
- Oct 2021
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of tisagenlecleucel in acute lymphoblastic leukemia (ALL), sponsored by Novartis. Started Oct 2020; status: terminated.
02
Drugs
tisagenlecleucel
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT04225676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04225676.